Unicycive Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Unicycive is a clinical-stage biotechnology company developing Renazorb for hyperphosphatemia in chronic kidney disease and UNI 494 for acute kidney injury. It had no product sales; reported revenue was licensing revenue.
Key financial metrics
| Metric | Q1 2022 | Q1 2023 / March 31, 2023 |
|---|---|---|
| Licensing revenue | $0 | $675,000 |
| Research and development expense | $1.933 million | $3.030 million |
| General and administrative expense | $1.604 million | $1.847 million |
| Operating loss | $3.537 million | $4.202 million |
| Net loss | $3.537 million | $14.575 million |
| Net loss per common share, basic and diluted | $0.24 | $0.97 |
| Cash and cash equivalents | — | $24.332 million |
| Net cash used in operating activities | $2.957 million | $3.920 million |
At March 31, 2023, total assets were $27.202 million, current liabilities were $15.970 million, and total liabilities were $16.685 million. Current liabilities included a $13.206 million warrant liability, which is a fair-value accounting liability rather than conventional funded debt. The company also reported $991,000 of operating lease liabilities. No conventional borrowings were reported at quarter-end.
There are no meaningful product gross margins to report because revenue consisted of licensing fees, not product sales. The filing does not provide a clear operating margin measure.
Changes versus the prior comparable period
- Licensing revenue rose from zero to $675,000, from the upfront payment under a February 2023 Renazorb license with Lotus International for South Korea.
- R&D expense increased 57% to $3.030 million, principally because drug-development costs rose by $962,000. G&A expense increased 15% to $1.847 million, mainly due to higher consulting and professional-services costs.
- Operating loss increased by $665,000. Net loss increased by $11.038 million, driven chiefly by a $10.375 million noncash loss from remeasurement of warrants issued in connection with the March financing.
- Operating cash use increased from $2.957 million to $3.920 million. Financing activities provided $27.797 million in Q1 2023, primarily from the preferred-stock placement; cash rose from $455,000 at year-end 2022 to $24.332 million at March 31, 2023.
Financing, outlook, and risks
- On March 3, 2023, the company issued 30,190 Series A-1 preferred shares for $30.0 million gross proceeds and approximately $28.0 million net proceeds after fees and expenses. The financing provides for up to $130 million gross proceeds, including potential warrant exercises tied to Renazorb milestones. The company said proceeds would support a U.S. NDA submission for Renazorb and, if approved, a U.S. commercial launch.
- Conversion of the preferred stock and issuance of the related warrants require stockholder approval. The filing said the company intended to seek approval at its June 2023 annual meeting. The preferred stock accrues an 8% annual cumulative dividend, rising to 14% if approval is not obtained at the first stockholder meeting after the offering. If approval is not obtained within one year, holders may elect redemption under the stated terms.
- Potential warrant exercise proceeds depend on events including FDA approval, TDAPA approval, and four quarters of commercial sales after TDAPA approval. The warrants are liability-classified and valued using Level 3 assumptions; their fair value increased from $2.831 million at issuance to $13.206 million at quarter-end.
- Management expected continued operating losses and R&D spending to increase. After the March financing, management stated it believed cash resources were sufficient to fund operations for at least one year after the financial statements became available to issue. The company also said it expects to need substantial additional capital; no specific earnings or revenue guidance was provided.
- Key risks include clinical and regulatory uncertainty, manufacturing and commercialization execution, future financing availability and potential dilution. The company disclosed no material legal proceedings and no material changes to the risk factors in its 2022 Form 10-K.
- Disclosure controls and internal control over financial reporting were deemed ineffective as of March 31, 2023 due to a material weakness involving insufficient accounting staff and expertise, inadequate formal controls, and insufficient review of certain transactions. Management planned hiring, outside expert assistance, and control enhancements, with remediation targeted by year-end 2023.
Important facts for investors to verify
- Whether stockholders approved the financing-related conversions and warrants, and the current status and terms of any amendments to the preferred-stock designation.
- Renazorb’s NDA submission and FDA review status, and the prospects and timing for FDA approval, TDAPA eligibility, and commercial launch.
- Actual cash burn and runway relative to management’s estimate, including the funding required to advance both Renazorb and UNI 494.
- The potential dilution, redemption exposure, dividend accruals, and contingent warrant exercise proceeds under the preferred financing.
- Subsequent warrant fair-value changes and the reasonableness of the significant unobservable valuation assumptions.
- Progress in remediating the material weakness in financial reporting controls and whether the targeted year-end 2023 remediation was achieved.